Parkinson's disease (PD) is a debilitating and progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons in the substantia nigra, a brain region essential for motor ...

Bial announced that 75% of patients enrolled in its Phase 2b clinical study ACTIVATE completed the double-blind treatment period of 78 weeks.

In a step toward treating mitochondrial diseases, researchers at the University Medical Center Utrecht and their colleagues have used mitochondrial base editing (mtBE) to successfully edit harmful ...

Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting tens of millions of people worldwide, and it is the most common cause of dementia. Early-onset AD is typically associated ...

Wounded and elderly patients are being evacuated by train from embattled east Ukraine - Copyright AFP Ishara S. KODIKARA Wounded and elderly patients are being ...

Researchers at Google DeepMind claim to have built an AI model that can pinpoint which genetic mutations are likely to cause disease, according to a new study in the journal Science. The new model, ...

Practices and Views of US Oncologists and Genetic Counselors Regarding Patient Recontact After Variant Reclassification: Results of a Nationwide Survey Long-standing clinical predictors of cancer ...

PORTO, Portugal, May 25, 2023 /PRNewswire/ -- BIAL - R&D Investments S.A (BIAL R&D), a subsidiary of BIAL Holding, S.A., today announced the dosing of the first patient in its Phase 2 clinical trial ...

A comprehensive analysis of over 500,000 human protein variants reveals that 60% of disease-causing missense mutations reduce protein stability In a recent study published in Nature, researchers used ...

Such a puzzle since the patient had neither CVD risk factors nor atherosclerotic changes ...